Katharina Wieser
Plus aucun poste en cours
Profil
Katharina Wieser worked as a Director of Finance & Communications at Themis Bioscience GmbH, a Principal at Baxter Vaccine AG, and a Principal at news verlag.
Anciens postes connus de Katharina Wieser
| Sociétés | Poste | Fin |
|---|---|---|
| news verlag | Corporate Officer/Principal | - |
Baxter Vaccine AG
 Baxter Vaccine AG Pharmaceuticals: MajorHealth Technology Baxter Vaccine AG manufactures vaccines and medical therapies. The firm offers TBE vaccine and a vaccine against group C meningococcal meningitis. It provides Lyme Borreliosis and modified vaccines. The company was founded in 1953 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - |
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Baxter Vaccine AG
Baxter Vaccine AG Pharmaceuticals: MajorHealth Technology Baxter Vaccine AG manufactures vaccines and medical therapies. The firm offers TBE vaccine and a vaccine against group C meningococcal meningitis. It provides Lyme Borreliosis and modified vaccines. The company was founded in 1953 and is headquartered in Vienna, Austria. | Health Technology |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Health Technology |
| news verlag |
